Class Action Signal

Class Action Signal

Class ActionsNews
Class ActionsNewsAboutContact
Public case informationLast updated

Regeneron Securities Fraud Class Action

Regeneron Pharmaceuticals · Regeneron securities and the Fianlimab-Libtayo clinical trial · New Filing

About this case

Investors allege that Regeneron Pharmaceuticals made false or misleading statements about the likely success of its Phase III Fianlimab-Libtayo study, including its ability to achieve the primary endpoint and demonstrate clinical differentiation. The securities class action was described as not yet certified, and an opportunity to seek appointment as lead plaintiff was announced; the current procedural stage beyond that is not specified.

Case overview

Defendant company
Regeneron Pharmaceuticals
Product or service
Regeneron securities and the Fianlimab-Libtayo clinical trial
Case name
Cheathem v. Regeneron Pharm., Inc., et al.
Court case number
26-cv-6026
Case status
New Filing
Lawsuit type
Securities
Reported harm
Misrepresentation

Important dates

Lead plaintiff application
Law Firm Case Intake

Participation information

Lead plaintiff application

Investors who purchased Regeneron securities during the stated class period and allegedly suffered a loss were encouraged to contact the Schall Law Firm regarding the case.

Contact the Schall Law Firm regarding the opportunity to seek appointment as lead plaintiff.

Type
Lead Plaintiff
Status
Deadline passed
Reported proof requirement
Unclear

Law Firm Case Intake

Investors in Regeneron securities were invited to submit their information to the law firm regarding the litigation.

Submit information through the linked Bleichmar Fonti & Auld LLP page.

Type
Law Firm Signup
Status
Deadline passed
Contact law firm
Press release describing the lawsuit Original case announcement

Sources